Literature DB >> 9826634

X-ray absorption fine-structure spectroscopy studies of Fe sites in natural human neuromelanin and synthetic analogues.

A J Kropf1, B A Bunker, M Eisner, S C Moss, L Zecca, A Stroppolo, P R Crippa.   

Abstract

X-ray absorption fine-structure spectroscopy is used to study the local environment of the iron site in natural (human) neuromelanin extracted from substantia nigra tissue and in various synthetic neuromelanins. All the materials show Fe centered in a nearest neighbor sixfold (distorted) oxygen octahedron; the Fe-O distances, while slightly different in the natural and synthetic neuromelanin, are both approximately 2.0 A. Appreciable differences arise, however, in the second (and higher) coordination shells. In this case the synthetic melanin has the four planar oxygens bound to carbon rings with Fe-C distances of approximately 2.82 and 4.13 A; the human sample does not show the 2.82 A link but instead indicates a double shell at approximately 3.45 and 3.78 A.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826634      PMCID: PMC1299985          DOI: 10.1016/S0006-3495(98)77755-0

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  12 in total

1.  The chemical characterization of melanin contained in substantia nigra of human brain.

Authors:  L Zecca; C Mecacci; R Seraglia; E Parati
Journal:  Biochim Biophys Acta       Date:  1992-01-16

2.  Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra.

Authors:  M Gerlach; A X Trautwein; L Zecca; M B Youdim; P Riederer
Journal:  J Neurochem       Date:  1995-08       Impact factor: 5.372

3.  X-ray characterization of melanins--II.

Authors:  J Cheng; S C Moss; M Eisner
Journal:  Pigment Cell Res       Date:  1994-08

4.  Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study.

Authors:  T Shima; T Sarna; H M Swartz; A Stroppolo; R Gerbasi; L Zecca
Journal:  Free Radic Biol Med       Date:  1997       Impact factor: 7.376

5.  Iron, melanin and dopamine interaction: relevance to Parkinson's disease.

Authors:  D Ben-Shachar; M B Youdim
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1993-01       Impact factor: 5.067

6.  Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease.

Authors:  D Ben-Shachar; P Riederer; M B Youdim
Journal:  J Neurochem       Date:  1991-11       Impact factor: 5.372

Review 7.  Modulation by neuromelanin of the availability and reactivity of metal ions.

Authors:  H M Swartz; T Sarna; L Zecca
Journal:  Ann Neurol       Date:  1992       Impact factor: 10.422

8.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

9.  Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis.

Authors:  K Jellinger; E Kienzl; G Rumpelmair; P Riederer; H Stachelberger; D Ben-Shachar; M B Youdim
Journal:  J Neurochem       Date:  1992-09       Impact factor: 5.372

10.  Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain.

Authors:  L Zecca; R Pietra; C Goj; C Mecacci; D Radice; E Sabbioni
Journal:  J Neurochem       Date:  1994-03       Impact factor: 5.372

View more
  12 in total

Review 1.  The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.

Authors:  Alessandra Gaeta; Robert C Hider
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

2.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 3.  Neuromelanin of the human substantia nigra: an update.

Authors:  Fabio A Zucca; Emy Basso; Francesca A Cupaioli; Emanuele Ferrari; David Sulzer; Luigi Casella; Luigi Zecca
Journal:  Neurotox Res       Date:  2013-10-24       Impact factor: 3.911

Review 4.  Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour.

Authors:  L Zecca; D Tampellini; M Gerlach; P Riederer; R G Fariello; D Sulzer
Journal:  Mol Pathol       Date:  2001-12

5.  Synthesis and structural characterization of soluble neuromelanin analogs provides important clues to its biosynthesis.

Authors:  Emanuele Ferrari; Mireille Engelen; Enrico Monzani; Michela Sturini; Stefania Girotto; Luigi Bubacco; Luigi Zecca; Luigi Casella
Journal:  J Biol Inorg Chem       Date:  2012-10-31       Impact factor: 3.358

Review 6.  Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.

Authors:  Fabio A Zucca; Juan Segura-Aguilar; Emanuele Ferrari; Patricia Muñoz; Irmgard Paris; David Sulzer; Tadeusz Sarna; Luigi Casella; Luigi Zecca
Journal:  Prog Neurobiol       Date:  2015-10-09       Impact factor: 11.685

7.  Structural insight into [Fe-S2-Mo] motif in electrochemical reduction of N2 over Fe1-supported molecular MoS2.

Authors:  Jianwei Zheng; Simson Wu; Lilin Lu; Chen Huang; Ping-Luen Ho; Angus Kirkland; Tim Sudmeier; Rosa Arrigo; Diego Gianolio; Shik Chi Edman Tsang
Journal:  Chem Sci       Date:  2020-11-12       Impact factor: 9.825

Review 8.  Interaction of Neuromelanin with Xenobiotics and Consequences for Neurodegeneration; Promising Experimental Models.

Authors:  Andrea Capucciati; Fabio A Zucca; Enrico Monzani; Luigi Zecca; Luigi Casella; Tim Hofer
Journal:  Antioxidants (Basel)       Date:  2021-05-21

Review 9.  The role of iron in neurodegenerative disorders: insights and opportunities with synchrotron light.

Authors:  Joanna F Collingwood; Mark R Davidson
Journal:  Front Pharmacol       Date:  2014-08-19       Impact factor: 5.810

Review 10.  Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease.

Authors:  David Sulzer; Clifford Cassidy; Guillermo Horga; Un Jung Kang; Stanley Fahn; Luigi Casella; Gianni Pezzoli; Jason Langley; Xiaoping P Hu; Fabio A Zucca; Ioannis U Isaias; Luigi Zecca
Journal:  NPJ Parkinsons Dis       Date:  2018-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.